HPLC-MS/MS-Mediated Analysis of the Pharmacokinetics, Bioavailability, and Tissue Distribution of Schisandrol B in Rats

Table 3

Recovery and matrix effects of Schisandrol B in plasma and tissues homogenate samples (n = 6).

Samples	Conc. (ng/mL)	Extraction recovery (mean ± SD)	Matric effect (mean ± SD)
Plasma	15	75.55 ± 11.85	103.68 ± 9.77
	150	87.72 ± 10.91	110.32 ± 13.18
	1500	87.44 ± 11.36	105.71 ± 5.72
Heart	2	78.9 ± 9.10	101.31 ± 8.79
	40	76.7 ± 4.40	99.88 ± 3.09
	800	75.5 ± 10.70	101.38 ± 14.30
Liver	2	97.89 ± 6.19	106.57 ± 12.41
	40	96.03 ± 10.05	114.08 ± 4.92
	800	87.79 ± 10.74	107.39 ± 7.02
Spleen	2	83.33 ± 8.40	94.56 ± 12.11
	40	91.12 ± 5.47	101.61 ± 9.46
	800	79.99 ± 3.04	105.42 ± 2.18
Lung	2	93.19 ± 5.16	107.50 ± 4.81
	40	96.52 ± 6.81	95.92 ± 12.51
	800	92.41 ± 12.10	99.31 ± 8.43
Kidney	2	86.40 ± 9.95	113.13 ± 3.42
	40	91.03 ± 6.55	101.98 ± 3.54
	800	86.45 ± 5.00	105.82 ± 1.66
Brain	2	91.30 ± 3.29	90.62 ± 7.57
	40	94.26 ± 1.79	93.93 ± 9.74
	800	82.60 ± 9.80	96.85 ± 13.33